Trial · NCT06531109
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24 | 24 weeks from initiation of the treatment | SALT score is used to calculate the severity of alopecia areata. Physician calculate it by summing the percentage of hair loss in different regions of scalp. |
| Secondary | Demographic characteristic of participants: Age, sex, race, ethnicity, socio-economic status, area of residence, smoking status | Baseline | Number/percentage of patients by age, sex, race, ethnicity, socio-economic status, area of residence, smoking status. Race and ethnicity variables will only be collected in participating countries where it is allowed. |
| Secondary | Demographic Characteristic of Participants: Date of Initial AA diagnosis | Baseline | |
| Secondary | Demographic Characteristics of participants: Duration of AA since diagnosis | Baseline | |
| Secondary | Demographic characteristics of participants: Duration of current AA Episode | Baseline | |
| Secondary | Demographic Characteristic of Participants: Predominant AA phenotype | Baseline | Predominant AA phenotype (eg, patchy; ophiasis; AT; AU, etc |
| Secondary | Clinical Characteristics of participants: Severity of Alopecia Tool (SALT) Score | Baseline | SALT score is used to calculate the severity of alopecia areata. |
| Secondary | Clinical characteristics of participants: Eyelash Assessment (ELA) score | Baseline | ELA score is used to calculate the severity of the involvement of eyelashes. |
| Secondary | Clinical Characteristics of participants: Eyebrow Assessment (EBA) Score | Baseline | EBA score is used to calculate the severity of the involvement of eyebrows |
| Secondary | Clinical Characteristics of participants: number of affected nails | Baseline | |
| Secondary | Clinical Characteristics of participants: Presence of Beard involvement | Baseline | Determine whether the beard is affected or not. |
| Secondary | AA treatment history of participants: number of patients with prior AA treatments | Baseline | |
| Secondary | AA treatment history of participants: prior AA treatment class and route | Baseline | |
| Secondary | AA treatment history of participants: duration of prior therapy / frequency | baseline | |
| Secondary | AA treatment history of the participants: total number of prior AA treatments | Baseline | |
| Secondary | RW effectiveness of ritlecitinib: proportion of patients with <20 in SALT score | week 24, 48, 72 and 96 | decrease in SALT score is the indicator of effectiveness. |
| Secondary | RW effectiveness of ritlecitinib: Proportion of patients with <10 | week 24, 48, 72 and 96 | Decrease in SALT score is the indicator of effectiveness |
| Secondary | RW effectiveness of ritlecitinib: Change from baseline in SALT score | week 24, 48, 72 and 96 | Decrease in SALT score is the indicator of effectiveness |
| Secondary | RW effectiveness of ritlecitinib: proportion of patient with improvement from abnormal baseline in Eyebrow Assessment score (EBA) | Week 24, 48, 72 and 96 | Improvement in EBA score will indicate ritlecitinib effectiveness in eyebrow involvement. |
| Secondary | RW effectiveness of ritlecitinib: proportion of patient with improvement from abnormal baseline in Eyelashes Assessment Score (ELA) | Week 24, 48, 72 and 96 | Improvement in ELA score will indicate ritlecitinib effectiveness in eyebrow involvement. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06531109/registered